Deciphera Pharmaceuticals, Inc. Restructuring Costs and Asset Impairment Charges
Deciphera Pharmaceuticals, Inc. reported Restructuring Costs and Asset Impairment Charges of $2.93 million for the 3-month period ending 2021-12-31, per its 10-K filed 2024-02-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:RestructuringCostsAndAssetImpairmentCharges · last filed 2024-02-07
- Deciphera Pharmaceuticals, Inc. restructuring costs and asset impairment charges for the quarter ending 2021-12-31 was $2.93M.
| Period end | Restructuring Costs and Asset Impairment Charges 3 month |
|---|---|
| 2021-12-31 | $2.93M 10-K · filed 2024-02-07 |